{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:07:55Z","timestamp":1778018875367,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40265-013-0125-0","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T14:21:48Z","timestamp":1380637308000},"page":"1711-1722","source":"Crossref","is-referenced-by-count":40,"title":["A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis"],"prefix":"10.1007","volume":"73","author":[{"given":"Rachel","family":"Jawahar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Unsong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate L.","family":"Lapane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,2]]},"reference":[{"key":"125_CR1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221\u201331.","journal-title":"Lancet."},{"key":"125_CR2","doi-asserted-by":"crossref","unstructured":"Brichetto G, Messmer Uccelli M, Mancardi GL, Solaro C. Symptomatic medication use in multiple sclerosis. Mult Scler. 2003;9:458\u201360.","DOI":"10.1191\/1352458503ms957oa"},{"key":"125_CR3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.1973.03220050047010","volume":"223","author":"CD Aring","year":"1973","unstructured":"Aring CD. Pain in multiple sclerosis. JAMA. 1973;223:547.","journal-title":"JAMA."},{"key":"125_CR4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pain.2007.08.024","volume":"137","author":"AB O\u2019Connor","year":"2008","unstructured":"O\u2019Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008;137:96\u2013111.","journal-title":"Pain."},{"key":"125_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrneurol.2011.120","volume":"7","author":"C Solaro","year":"2011","unstructured":"Solaro C, Uccelli MM. Management of pain in multiple sclerosis: a pharmacological approach. Nat Rev Neurol. 2011;7:519\u201327.","journal-title":"Nat Rev Neurol."},{"key":"125_CR6","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1517\/14656566.2011.607162","volume":"12","author":"A Truini","year":"2011","unstructured":"Truini A, Galeotti F, Cruccu G. Treating pain in multiple sclerosis. Expert Opin Pharmacother. 2011;12:2355\u201368.","journal-title":"Expert Opin Pharmacother."},{"key":"125_CR7","doi-asserted-by":"crossref","unstructured":"Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113\u2013e88.","DOI":"10.1111\/j.1468-1331.2010.02999.x"},{"key":"125_CR8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","volume":"65","author":"DJ Rog","year":"2005","unstructured":"Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812\u20139.","journal-title":"Neurology."},{"key":"125_CR9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1191\/1352458502ms795rr","volume":"8","author":"S Paisley","year":"2002","unstructured":"Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8:319\u201329.","journal-title":"Mult Scler."},{"key":"125_CR10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clineuro.2011.10.044","volume":"114","author":"L Santi De","year":"2012","unstructured":"De Santi L, Annunziata P. Symptomatic cranial neuralgias in multiple sclerosis: clinical features and treatment. Clin Neurol Neurosurg. 2012;114:101\u20137.","journal-title":"Clin Neurol Neurosurg."},{"key":"125_CR11","doi-asserted-by":"crossref","unstructured":"Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4):CD001332.","DOI":"10.1002\/14651858.CD001332"},{"key":"125_CR12","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","DOI":"10.1136\/bmj.b2535"},{"key":"125_CR13","doi-asserted-by":"crossref","unstructured":"Schumacher M, Hussain R, Gago N, Oudinet JP, Mattern C, Ghoumari AM. Progesterone synthesis in the nervous system: implications for myelination and myelin repair. Frontiers Neurosci. 2012;6:10.","DOI":"10.3389\/fnins.2012.00010"},{"key":"125_CR14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d. Ann Neurol. 2005;58:840\u20136.","journal-title":"Ann Neurol."},{"key":"125_CR15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/oxfordjournals.bmb.a071393","volume":"33","author":"W McDonald","year":"1977","unstructured":"McDonald W, Halliday A. Diagnosis and classification of multiple sclerosis. Br Med Bull. 1977;33:4\u20138.","journal-title":"Br Med Bull."},{"key":"125_CR16","doi-asserted-by":"crossref","unstructured":"Poser C, Brinar VV. Diagnostic criteria for multiple sclerosis. Clin Neurol Neurosurg. 2001;103:1\u201311.","DOI":"10.1016\/S0303-8467(00)00125-6"},{"key":"125_CR17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(74)90884-8","volume":"2","author":"EC Huskisson","year":"1974","unstructured":"Huskisson EC. Measurement of pain. Lancet. 1974;2:1127\u201331.","journal-title":"Lancet."},{"key":"125_CR18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149\u201358.","journal-title":"Pain."},{"key":"125_CR19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","volume":"1","author":"R Melzack","year":"1975","unstructured":"Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277\u201399.","journal-title":"Pain."},{"key":"125_CR20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr. Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I: conceptual framework and item selection. Med Care. 1992;30:473\u201383.","journal-title":"Med Care."},{"key":"125_CR21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/ard.37.4.378","volume":"37","author":"WW Downie","year":"1978","unstructured":"Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978;37:378\u201381.","journal-title":"Ann Rheum Dis."},{"key":"125_CR22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u201352.","journal-title":"Neurology."},{"key":"125_CR23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1469-185X.2007.00027.x","volume":"82","author":"S Nakagawa","year":"2007","unstructured":"Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc. 2007;82:591\u2013605.","journal-title":"Biol Rev Camb Philos Soc."},{"key":"125_CR24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1037\/1082-989X.7.1.105","volume":"7","author":"SB Morris","year":"2002","unstructured":"Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7:105\u201325.","journal-title":"Psychol Methods."},{"key":"125_CR25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1037\/a0024338","volume":"141","author":"CO Fritz","year":"2012","unstructured":"Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen. 2012;141:2\u201318.","journal-title":"J Exp Psychol Gen."},{"key":"125_CR26","unstructured":"Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2011; No. Version 5.1.0 (updated March 2011)."},{"key":"125_CR27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1212\/01.wnl.0000336533.19610.1b","volume":"71","author":"J French","year":"2008","unstructured":"French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology. 2008;71:1634\u20138.","journal-title":"Neurology."},{"key":"125_CR28","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G","volume":"60","author":"B Fishman","year":"1987","unstructured":"Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC, Foley KM. The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer. 1987;60:1151\u20138.","journal-title":"Cancer."},{"issue":"5","key":"125_CR29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002508-200409000-00005","volume":"20","author":"S Keller","year":"2004","unstructured":"Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20(5):309\u201318.","journal-title":"Clin J Pain."},{"key":"125_CR30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/j.1532-2149.2011.00073.x","volume":"16","author":"M Falah","year":"2012","unstructured":"Falah M, Madsen C, Holbech JV, Sindrup SH. A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. Eur J Pain. 2012;16:860\u20139.","journal-title":"Eur J Pain."},{"key":"125_CR31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1468-1331.2008.02496.x","volume":"16","author":"S Rossi","year":"2009","unstructured":"Rossi S, Mataluni G, Codeca C, et al. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol. 2009;16:360\u20136.","journal-title":"Eur J Neurol."},{"key":"125_CR32","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.clinthera.2007.09.023","volume":"29","author":"B Breuer","year":"2007","unstructured":"Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, Portenoy RK. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther. 2007;29:2022\u201330.","journal-title":"Clin Ther."},{"key":"125_CR33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/135245859700300407","volume":"3","author":"MK Houtchens","year":"1997","unstructured":"Houtchens MK, Richert JR, Sami A, Rose JW. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler. 1997;3:250\u20133.","journal-title":"Mult Scler."},{"key":"125_CR34","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00415-009-5203-6","volume":"256","author":"C Solaro","year":"2009","unstructured":"Solaro C, Boehmker M, Tanganelli P. Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. J Neurol. 2009;256:1773\u20134.","journal-title":"J Neurol."},{"key":"125_CR35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10072-007-0811-3","volume":"28","author":"C Solaro","year":"2007","unstructured":"Solaro C, Restivo D, Mancardi GL, Tanganelli P. Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurol Sci. 2007;28:156\u20138.","journal-title":"Neurol Sci."},{"key":"125_CR36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/AJP.0b013e318190862b","volume":"25","author":"A Chitsaz","year":"2009","unstructured":"Chitsaz A, Janghorbani M, Shaygannejad V, Ashtari F, Heshmatipour M, Freeman J. Sensory complaints of the upper extremities in multiple sclerosis: relative efficacy of nortriptyline and transcutaneous electrical nerve stimulation. Clin J Pain. 2009;25:281\u20135.","journal-title":"Clin J Pain."},{"key":"125_CR37","unstructured":"Eli Lilly & Co. Duloxetine for multiple sclerosis pain [ClinicalTrials.gov identifier NCT00755807]. US National Institutes of Health, ClinicalTrials.gov. Available from URL: http:\/\/www.clinicaltrials.gov . Accessed 28 Aug 2013."},{"key":"125_CR38","unstructured":"GW Pharmaceuticals Ltd. Sativex versus placebo when added to existing treatment for central neuropathic pain in MS [ClinicalTrials.gov identifier NCT00391079]. US National Institutes of Health, ClinicalTrials.gov. Available from URL: http:\/\/www.clinicaltrials.gov . Accessed 28 Aug 2013."},{"key":"125_CR39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","volume":"10","author":"DT Wade","year":"2004","unstructured":"Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434\u201341.","journal-title":"Mult Scler."},{"key":"125_CR40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.38149.566979.AE","volume":"329","author":"KB Svendsen","year":"2004","unstructured":"Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253.","journal-title":"BMJ."},{"key":"125_CR41","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.20828","volume":"59","author":"HS Panitch","year":"2006","unstructured":"Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan\/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59:780\u20137.","journal-title":"Ann Neurol."},{"key":"125_CR42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","volume":"68","author":"BA Cree","year":"2010","unstructured":"Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68:145\u201350.","journal-title":"Ann Neurol."},{"key":"125_CR43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/eujp.2001.0307","volume":"6","author":"S Kalman","year":"2002","unstructured":"Kalman S, Osterberg A, Sorensen J, Boivie J, Bertler A. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain. 2002;6:69\u201380.","journal-title":"Eur J Pain."},{"key":"125_CR44","doi-asserted-by":"crossref","unstructured":"Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009;9:59.","DOI":"10.1186\/1471-2377-9-59"},{"key":"125_CR45","first-page":"254","volume":"13","author":"N Olney","year":"2010","unstructured":"Olney N, Rosen H. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain. IDrugs. 2010;13:254\u201365.","journal-title":"IDrugs."},{"key":"125_CR46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ana.22093","volume":"68","author":"EP Pioro","year":"2010","unstructured":"Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693\u2013702.","journal-title":"Ann Neurol."},{"key":"125_CR47","unstructured":"Hobson K. Lawmakers aren\u2019t laughing about Avanir\u2019s price for nuedexta. Wall Street J. 2011. Available from: http:\/\/blogs.wsj.com\/health\/2011\/05\/25\/lawmakers-arent-laughing-about-avanirs-price-for-nuedexta\/ . Accessed 6 March 2013."},{"key":"125_CR48","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/jnnp.2008.144964","volume":"81","author":"T Saarto","year":"2010","unstructured":"Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81:1372\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"125_CR49","doi-asserted-by":"crossref","unstructured":"Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;(3):CD007938.","DOI":"10.1002\/14651858.CD007938.pub2"},{"key":"125_CR50","doi-asserted-by":"crossref","unstructured":"Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3):CD007076.","DOI":"10.1002\/14651858.CD007076.pub2"},{"key":"125_CR51","doi-asserted-by":"crossref","unstructured":"Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009;(4):CD007115.","DOI":"10.1002\/14651858.CD007115.pub2"},{"key":"125_CR52","doi-asserted-by":"crossref","unstructured":"Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006;(3):CD006146.","DOI":"10.1002\/14651858.CD006146"},{"key":"125_CR53","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.04.007","volume":"122","author":"AB O\u2019Connor","year":"2009","unstructured":"O\u2019Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122:S22\u201332.","journal-title":"Am J Med."},{"key":"125_CR54","doi-asserted-by":"crossref","unstructured":"Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012;7:CD008943.","DOI":"10.1002\/14651858.CD008943.pub2"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0125-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0125-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T09:52:51Z","timestamp":1716025971000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0125-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":54,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0125-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}